Wave Life Sciences spotlights obesity contender Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 30 October, 2025

Start your year where biopharma sets its agenda. Join Endpoints News and industry leaders in San Francisco as we unpack the forces shaping dealmaking, China's emerging role and regulatory shifts. Save $200 with Early Bird rates — reserve your spot today.

presented by Gene Ther­a­py for the Mass­es: Ex­pand­ing the Treat­ment Par­a­digm with HCAd

SPOTLIGHT What Novo Nordisk might be planning to turn the ship around

news Updated: Novo again tries to get Metsera in surprise bid; Pfizer alleges move is 'in violation of law' Lilly blows past revenue benchmarks, again raises full-year outlook Takeda makes some pipeline cuts, says generic competition softens Q2 sales Wave Life Sciences’ obesity biomarker data raise hopes for future readouts Roche promises $1B to China biotech for preclinical COPD bispecific Tubulis upsizes Series C to $401M to ‘push the boundaries of ADCs’ Ventus stops Phase 2 of NLRP3 inhibitor that was being tested in Parkinson’s

Nov 12 2:30pm ET From JP Morgan to the next wave: What's driving biotech in 2026 sponsored by Precision AQ Nov 13 11:00am ET Driving down the cost: Optimising CGT with the right CDMO partner sponsored by OXB

Biopharma is entering a new era of AI-driven discovery and precision medicine — but growth is challenged by regulatory shifts and global uncertainty. Join us in London to hear from the leaders shaping what’s next.

endpoints pharma BIO chief Crowley tells senators China could pass US biotech within two years FDA makes major move to reduce regulatory red tape for biosimilars Blockbuster weight loss drugs could be cost-effective even at higher prices, ICER says Thermo Fisher to buy data solutions-focused Clario for up to $9.4B Novo Nordisk's direct-to-patient platform gains momentum as self-pay sales rise Lilly budgets $1.2B for GLP-1 pill factory in Puerto Rico

in case you missed it 1. Exclusive: Breaking up immune webs called NETs may offer new way to treat autoimmune disease, early data suggest 2. GSK trims pipeline, bumps guidance in Emma Walmsley’s last earnings report •  GSK confirms IRA negotiations for Trelegy are complete, says they met expectations 3. After this year's Nobel Prize, the first results for a CAR-Treg for autoimmune disease are in